CAS NO: | 1222102-29-5 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Evogliptin (DA-1229) is an orally activeDPP4inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducingautophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation[1][2][3][4]. | ||||||||
IC50& Target | DPP4[1][2][3][4]. | ||||||||
体外研究 (In Vitro) | Evogliptin (2.49 mM; 12 h) efficiently inhibits mDPP4 (membrane DPP4) enzymatic activity in PWM-induced H9 Th1 cells[1]. Cell Viability Assay[1]
| ||||||||
体内研究 (In Vivo) | Evogliptin (100, 300 mg/kg; in animal feedings; single daily for 10 weeks) exhibits antidiabetic effects on HFD/STZ mice and improves glucose intolerance and insulin resistance[3].
| ||||||||
Clinical Trial | |||||||||
分子量 | 401.42 | ||||||||
Formula | C19H26F3N3O3 | ||||||||
CAS 号 | 1222102-29-5 | ||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |